Scientific and Performance Evidence
Patient centered development of the AEROCHAMBER2GO* device
Patients were actively involved in all stages of the development process including: understanding the patient needs and therefore problems to solve, interactive involvement in concept development, feedback on functionality and appearance, and handling / usability.
Download
Patients preferred compared to other portable spacer devices
Device preference study showed the AEROCHAMBER2GO* prototype was preferred by patients compared to the A2A spacer and that patients were very likely to use while on-the-go.
Download
Evaluation of the AEROCHAMBER2GO* device with Zenhale† MDI
This laboratory study evaluated the medication delivery performance when using a LABA (Formoterol) containing combination MDI with and without a new portable AEROCHAMBER2GO* 2 in 1 chamber and protective case.
Download
Laboratory evaluation of the AEROCHAMBER2GO* device use with Foster† MDI
The AEROCHAMBER2GO* 2 in 1 chamber and protective case delivered similar fine particle delivery after a simulated 2-second delay to the Foster† MDI alone, when the pMDI alone was tested with simulated perfect technique (no delay). In addition, the large particles that could be deposited in the oropharynx and potentially lead to side effects were reduced more than ten fold when using the AEROCHAMBER2GO* device compared to the MDI alone.
Download
Delivery comparable to the established AEROCHAMBER PLUS* FLOW-VU* chamber
Based on findings from this laboratory study, both the AEROCHAMBER2GO * device and AEROCHAMBER PLUS* FLOW-VU* chamber deliver similar amounts of salbutamol to the lungs. The valved spacers also provide the additional benefit of reduced oropharyngeal deposition compared to the MDI when used alone.
Download
Improved adherence and high patient satisfaction with AEROCHAMBER2GO* device
This initial post launch survey highlighted a substantial increase in use of spacers with pMDIs while ‘On the go’. The spacer’s improved ease of use, carrying and appearance may well have contributed to the noted increased adherence. Use of AEROCHAMBER2GO* spacer should be considered for all patients requiring a reliever pMDI when ‘On the go’
Download